Abstract

The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The improved outcomes with brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) vs cyclophosphamide, doxorubicin, vincristine, and prednisone in the ECHELON-2 trial are practice changing for common nodal CD30+ PTCLs. Questions regarding the optimal cutoff of CD30 expression for BV-CHP therapy and the efficacy and safety of BV-CHP in less common subtypes of CD30+ PTCL subtypes await clarification.

REFERENCES

REFERENCES
1.
Zain
JM
.
Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management
.
Am J Hematol
.
2019
;
94
(
8
):
929
-
946
.
2.
Swerdlow
SH
,
Campo
E
,
Pileri
SA
, et al
.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
.
Blood
.
2016
;
127
(
20
):
2375
-
2390
.
3.
Abouyabis
AN
,
Shenoy
PJ
,
Lechowicz
MJ
,
Flowers
CR
.
Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States
.
Leuk Lymphoma
.
2008
;
49
(
11
):
2099
-
2107
.
4.
Herrera
AF
,
Crosby-Thompson
A
,
Friedberg
JW
, et al
.
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network
.
Cancer
.
2014
;
120
(
13
):
1993
-
1999
.
5.
Hsi
ED
,
Horwitz
SM
,
Carson
KR
, et al
.
Analysis of peripheral T-cell lymphoma diagnostic workup in the United States
.
Clin Lymphoma Myeloma Leuk
.
2017
;
17
(
4
):
193
-
200
.
6.
Chihara
D
,
Fanale
MA
,
Miranda
RN
, et al
.
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
.
Br J Haematol
.
2017
;
176
(
5
):
750
-
758
.
7.
Ellin
F
,
Landström
J
,
Jerkeman
M
,
Relander
T
.
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
.
Blood
.
2014
;
124
(
10
):
1570
-
1577
.
8.
Carson
KR
,
Horwitz
SM
,
Pinter-Brown
LC
, et al
.
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States
.
Cancer
.
2017
;
123
(
7
):
1174
-
1183
.
9.
Abramson
JS
,
Feldman
T
,
Kroll-Desrosiers
AR
, et al
.
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
.
Ann Oncol
.
2014
;
25
(
11
):
2211
-
2217
.
10.
Janikova
A
,
Chloupkova
R
,
Campr
V
, et al
.
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients
.
Ann Hematol
.
2019
;
98
(
8
):
1961
-
1972
.
11.
Federico
M
,
Bellei
M
,
Marcheselli
L
, et al;
T cell Project Network
.
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network
.
Br J Haematol
.
2018
;
181
(
6
):
760
-
769
.
12.
Maurer
MJ
,
Ellin
F
,
Srour
L
, et al
.
International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma
.
J Clin Oncol
.
2017
;
35
(
36
):
4019
-
4026
.
13.
Advani
RH
,
Ansell
SM
,
Lechowicz
MJ
, et al
.
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-Cell Consortium Trial
.
Br J Haematol
.
2016
;
172
(
4
):
535
-
544
.
14.
Hapgood
G
,
Stone
JM
,
Zannino
D
, et al;
Australasian Leukaemia and Lymphoma Group
.
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma
.
Leuk Lymphoma
.
2019
;
60
(
4
):
904
-
911
.
15.
Reiman
T
,
Savage
KJ
,
Crump
M
, et al
.
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study
.
Leuk Lymphoma
.
2019
;
60
(
4
):
912
-
919
.
16.
Mahadevan
D
,
Unger
JM
,
Spier
CM
, et al
.
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350
.
Cancer
.
2013
;
119
(
2
):
371
-
379
.
17.
Gleeson
M
,
Peckitt
C
,
To
YM
, et al
.
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
.
Lancet Haematol
.
2018
;
5
(
5
):
e190
-
e200
.
18.
Horwitz
SM
,
Zelenetz
AD
,
Gordon
LI
, et al
.
NCCN guidelines insights: non-Hodgkin’s lymphomas, Version 3.2016
.
J Natl Compr Canc Netw
.
2016
;
14
(
9
):
1067
-
1079
.
19.
Dhawale
TM
,
Shustov
AR
.
Autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas: a histology-specific review
.
Hematol Oncol Clin North Am
.
2017
;
31
(
2
):
335
-
357
.
20.
Park
SI
,
Horwitz
SM
,
Foss
FM
, et al;
COMPLETE Investigators
.
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study [published correction appears in Cancer. 2019;125(21):3893]
.
Cancer
.
2019
;
125
(
9
):
1507
-
1517
.
21.
Feldman
T
,
Farber
CM
,
Choi
K
, et al
.
Treatment of peripheral T-cell lymphoma in community settings
.
Clin Lymphoma Myeloma Leuk
.
2017
;
17
(
6
):
354
-
361
.
22.
Rohlfing
S
,
Dietrich
S
,
Witzens-Harig
M
, et al
.
The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience
.
Ann Hematol
.
2018
;
97
(
7
):
1241
-
1250
.
23.
Fossard
G
,
Broussais
F
,
Coelho
I
, et al
.
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers
.
Ann Oncol
.
2018
;
29
(
3
):
715
-
723
.
24.
d’Amore
F
,
Relander
T
,
Lauritzsen
GF
, et al
.
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
.
J Clin Oncol
.
2012
;
30
(
25
):
3093
-
3099
.
25.
Casulo
C
,
O’Connor
O
,
Shustov
A
, et al
.
T-cell lymphoma: recent advances in characterization and new opportunities for treatment
.
J Natl Cancer Inst
.
2016
;
109
(
2
):
djw248
.
26.
Stein
H
,
Gerdes
J
,
Kirchner
H
,
Schaadt
M
,
Diehl
V
.
Hodgkin and Sternberg-Reed cell antigen(s) detected by an antiserum to a cell line (L428) derived from Hodgkin’s disease
.
Int J Cancer
.
1981
;
28
(
4
):
425
-
429
.
27.
Schwab
U
,
Stein
H
,
Gerdes
J
, et al
.
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells
.
Nature
.
1982
;
299
(
5878
):
65
-
67
.
28.
Dürkop
H
,
Latza
U
,
Hummel
M
,
Eitelbach
F
,
Seed
B
,
Stein
H
.
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease
.
Cell
.
1992
;
68
(
3
):
421
-
427
.
29.
Stein
H
,
Diehl
V
.
First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms
.
Hematol Oncol Clin North Am
.
2014
;
28
(
1
):
1
-
11
.
30.
Stein
H
,
Mason
DY
,
Gerdes
J
, et al
.
The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
.
Blood
.
1985
;
66
(
4
):
848
-
858
.
31.
Montes-Mojarro
IA
,
Steinhilber
J
,
Bonzheim
I
,
Quintanilla-Martinez
L
,
Fend
F
.
The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL)
.
Cancers (Basel)
.
2018
;
10
(
4
):
E107
.
32.
Sabattini
E
,
Pizzi
M
,
Tabanelli
V
, et al
.
CD30 expression in peripheral T-cell lymphomas
.
Haematologica
.
2013
;
98
(
8
):
e81
-
e82
.
33.
Garcia-Herrera
A
,
Song
JY
,
Chuang
SS
, et al
.
Nonhepatosplenic γδ T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation
.
Am J Surg Pathol
.
2011
;
35
(
8
):
1214
-
1225
.
34.
Pongpruttipan
T
,
Sukpanichnant
S
,
Assanasen
T
, et al
.
Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study
.
Am J Surg Pathol
.
2012
;
36
(
4
):
481
-
499
.
35.
Gammon
B
,
Gammon
BR
,
Kim
YH
,
Kim
J
.
Neurotropic gamma-delta T-cell lymphoma with CD30-positive lymphoid infiltrates
.
Am J Dermatopathol
.
2016
;
38
(
9
):
e133
-
e136
.
36.
Bossard
C
,
Dobay
MP
,
Parrens
M
, et al
.
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
.
Blood
.
2014
;
124
(
19
):
2983
-
2986
.
37.
Bisig
B
,
de Reyniès
A
,
Bonnet
C
, et al
.
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
.
Haematologica
.
2013
;
98
(
8
):
1250
-
1258
.
38.
Talpur
R
,
Chockalingam
R
,
Wang
C
,
Tetzlaff
MT
,
Duvic
M
.
A single-center experience with brentuximab vedotin in gamma delta T-cell lymphoma
.
Clin Lymphoma Myeloma Leuk
.
2016
;
16
(
2
):
e15
-
e19
.
39.
Gru
AA
,
Kim
J
,
Pulitzer
M
, et al
.
The use of central pathology review with digital slide scanning in advanced-stage mycosis fungoides andSézary syndrome: a multi-institutional and international pathology study
.
Am J Surg Pathol
.
2018
;
42
(
6
):
726
-
734
.
40.
Scarisbrick
JJ
,
Prince
HM
,
Vermeer
MH
, et al
.
Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model
.
J Clin Oncol
.
2015
;
33
(
32
):
3766
-
3773
.
41.
Kartan
S
,
Johnson
WT
,
Sokol
K
, et al
.
The spectrum of CD30+ T cell lymphoproliferative disorders in the skin
.
Chin Clin Oncol
.
2019
;
8
(
1
):
3
.
42.
Ansell
SM
,
Horwitz
SM
,
Engert
A
, et al
.
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma
.
J Clin Oncol
.
2007
;
25
(
19
):
2764
-
2769
.
43.
Forero-Torres
A
,
Leonard
JP
,
Younes
A
, et al
.
A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
.
Br J Haematol
.
2009
;
146
(
2
):
171
-
179
.
44.
Doronina
SO
,
Toki
BE
,
Torgov
MY
, et al
.
Development of potent monoclonal antibody auristatin conjugates for cancer therapy [published corrections appears in Nat Biotechnol. 2003;21:941]
.
Nat Biotechnol
.
2003
;
21
(
7
):
778
-
784
.
45.
Francisco
JA
,
Cerveny
CG
,
Meyer
DL
, et al
.
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
.
Blood
.
2003
;
102
(
4
):
1458
-
1465
.
46.
Younes
A
,
Bartlett
NL
,
Leonard
JP
, et al
.
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
.
N Engl J Med
.
2010
;
363
(
19
):
1812
-
1821
.
47.
Pro
B
,
Advani
R
,
Brice
P
, et al
.
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
.
J Clin Oncol
.
2012
;
30
(
18
):
2190
-
2196
.
48.
Pro
B
,
Advani
R
,
Brice
P
, et al
.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
.
Blood
.
2017
;
130
(
25
):
2709
-
2717
.
49.
Horwitz
SM
,
Advani
RH
,
Bartlett
NL
, et al
.
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
.
Blood
.
2014
;
123
(
20
):
3095
-
3100
.
50.
Fanale
MA
,
Horwitz
SM
,
Forero-Torres
A
, et al
.
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study
.
J Clin Oncol
.
2014
;
32
(
28
):
3137
-
3143
.
51.
Fanale
MA
,
Horwitz
SM
,
Forero-Torres
A
, et al
.
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
.
Blood
.
2018
;
131
(
19
):
2120
-
2124
.
52.
Horwitz
S
,
O’Connor
OA
,
Pro
B
, et al;
ECHELON-2 Study Group
.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
.
Lancet
.
2019
;
393
(
10168
):
229
-
240
.
53.
Schmitz
N
,
Trümper
L
,
Ziepert
M
, et al
.
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
.
Blood
.
2010
;
116
(
18
):
3418
-
3425
.
54.
Kim
YH
,
Tavallaee
M
,
Sundram
U
, et al
.
Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project
.
J Clin Oncol
.
2015
;
33
(
32
):
3750
-
3758
.
55.
Duvic
M
,
Tetzlaff
MT
,
Gangar
P
,
Clos
AL
,
Sui
D
,
Talpur
R
.
Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis
.
J Clin Oncol
.
2015
;
33
(
32
):
3759
-
3765
.
56.
Prince
HM
,
Kim
YH
,
Horwitz
SM
, et al;
ALCANZA study group
.
Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
.
Lancet
.
2017
;
390
(
10094
):
555
-
566
.
57.
Jagadeesh
D
,
Horwitz
SM
,
Bartlett
L
, et al
.
Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas
.
J Clin Oncol
.
2019
;
37
(
suppl 15
):
7543
.
58.
Zinzani
PL
,
Pellegrini
C
,
Chiappella
A
, et al
.
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
.
Blood
.
2017
;
129
(
16
):
2328
-
2330
.
You do not currently have access to this content.